Dataset from Prospective Cohort Study to Monitor the Emergence of SARS-CoV-2 Spike Viral Variants in Immunocompromised Non-hospitalized Patients Exposed to Sotrovimab in Great Britain: LUNAR Study

Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization and/or death when administered as early treatment in non-hospitalized patients that are at risk for progression to severe disease. Immunocompromised (IC) patients are prioritized to receive early treatment for COVID-19 as they are at high risk of disease progression, and because of their potential for prolonged viral shedding and the resulting increased risk of emergent viral mutations and potential onward community transmission.This genomic surveillance study will aim to describe changes in the SARS-CoV-2 spike protein observed in IC participants receiving sotrovimab as standard of clinical care in sentinel sites at a national level to assess potential emergence of viral variants.

索特罗维单抗（Sotrovimab）可结合至严重急性呼吸综合征冠状病毒（SARS-CoV）与SARS-CoV-2刺突蛋白受体结合基序以外的保守表位；临床研究证实，在存在重症进展风险的非住院患者中早期给药，可降低其住院及/或死亡风险。免疫功能低下（Immunocompromised，IC）患者被优先纳入COVID-19早期治疗人群，原因在于此类患者疾病进展风险较高，且可能出现病毒持续脱落，进而增加病毒突变株出现及后续社区传播风险。本基因组监测研究旨在针对国家级哨点临床机构中接受标准临床治疗方案的免疫功能低下受试者，描述其体内观察到的SARS-CoV-2刺突蛋白变化情况，以评估病毒变异株的潜在出现风险。